Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-17 08:30 |
The Nomination Committee’s proposal for the annual shareholders’ meeting in All…
|
English | 107.6 KB | ||
| 2019-04-17 08:30 |
Valberedningens förslag inför årsstämman i Alligator Bioscience AB (publ)
|
Swedish | 81.6 KB | ||
| 2019-04-17 08:01 | Swedish | 2.9 MB | |||
| 2019-04-17 08:00 | English | 2.8 MB | |||
| 2019-04-11 13:30 |
Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 anti…
|
English | 103.9 KB | ||
| 2019-04-11 13:30 |
Alligator Bioscience: Prekliniska data för den tumörlokaliserande CTLA-4-antikr…
|
Swedish | 78.9 KB | ||
| 2019-04-10 11:45 |
Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
|
English | 118.4 KB | ||
| 2019-04-10 11:45 |
Kallelse till årsstämma i Alligator Bioscience AB (publ)
|
Swedish | 97.7 KB | ||
| 2019-04-02 13:30 |
Alligator Bioscience: Nya prekliniska data för ATOR-1144 visar potential för ak…
|
Swedish | 82.6 KB | ||
| 2019-04-02 13:30 |
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential …
|
English | 107.0 KB | ||
| 2019-03-22 09:31 | English | 5.3 MB | |||
| 2019-03-22 09:30 | Swedish | 5.5 MB | |||
| 2019-03-18 13:30 |
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effect…
|
English | 106.5 KB | ||
| 2019-03-18 13:30 |
Alligator Bioscience: Nya prekliniska data visar att 4-1BB-antikroppen ATOR-101…
|
Swedish | 81.8 KB | ||
| 2019-03-07 11:45 |
Alligator Bioscience: Första patienten doserad i ATOR-1015 klinisk fas I-studie
|
Swedish | 79.6 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
